Since Sir George Beatson observed in 1896 that breast tumorsin premenopausal women sometimes regressed after oophorectomy,1numerous investigations have established that estrogen stimulatesthe growth of breast-cancer cells. Three newer strategies reducethe growth-stimulating signals of estrogen: interfering withthe binding of estrogen to its receptor, the primary mode ofaction of the antiestrogen agent tamoxifen in premenopausaland postmenopausal women; decreasing the estrogen levels inthe blood and the tumor, the mechanism of action of aromataseinhibitors in postmenopausal women; and destroying the estrogenreceptor, which is how the drug fulvestrant exerts its antitumoractivity.
From the Jules Bordet Institute, Brussels, Belgium.
This article has been cited by other articles:
Bruzzi, P.
(2008). Non-drug industry funded research. BMJ
336: 1-2
[Full Text]
Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., Hudis, C., Butler, J., Merkel, D., Kristal, A., Caan, B., Michaelson, R., Vinciguerra, V., Del Prete, S., Winkler, M., Hall, R., Simon, M., Winters, B. L., Elashoff, R. M.
(2006). Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI J Natl Cancer Inst
98: 1767-1776
[Abstract][Full Text]
Mann, B. S., Johnson, J. R., Kelly, R., Sridhara, R., Williams, G., Pazdur, R.
(2005). Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen. Clin. Cancer Res.
11: 5671-5677
[Abstract][Full Text]
(2004). Another Role for Aromatase Inhibitors in Breast Cancer?. JWatch General
2004: 1-1
[Full Text]